Usefulness of Methadone Plasma Concentration Measurement in Patients Receiving Nevirapine or Efavirenz

REFERENCES

• Mitty JA, Macalino GE, Bazerman LB, Loewenthal HG, Hogan JW, MacLeod CJ, Flanigan TP. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr 2005; 39(5):545–550.
   PubMed Web of Science ®Google Scholar
• Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study. Addiction 2008: 103(11) 1828–36
   Google Scholar
• Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006; 42(11):1628–1635.
   PubMed Web of Science ®Google Scholar
• Macalino GE, Hogan JW, Mitty JA, Bazerman LB, Delong AK, Loewenthal H, Caliendo AM, Flanigan TP. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 2007; 21(11):1473–1477.
   PubMed Web of Science ®Google Scholar
• Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84(2):188–194.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41(5):563–572.
   PubMed Web of Science ®Google Scholar
• Clarke SM, Mulcahy FM. Efavirenz therapy in drug users. HIV Med 2000; 1(Suppl. 1):15–17.
   Google Scholar
• Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001; 33(9):1595–1597.
   PubMed Web of Science ®Google Scholar
• Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001; 51(3):213–217.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. AIDS 2000; 14(9):1291–1292.
   Google Scholar
• Tossonian HK, Raffa JD, Grebely J, Trotter B, Viljoen M, Mead A, Khara M, McLean M, Duncan F, Fraser C, DeVlaming S, Conway B. Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program. J Acquir Immune Defic Syndr 2007; 45(3):324–327.
   Google Scholar
• McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002; 11(4):271–278.
   PubMed Web of Science ®Google Scholar
• Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13(8):957–962.
   PubMed Web of Science ®Google Scholar
• Arroyo E, Valenzuela B, Portilla J, Climent-Grana E, Perez-Ruixo JJ, Merino E. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Eur J Clin Pharmacol 2007; 63(7): 669–675.
   PubMed Web of Science ®Google Scholar
• Otero MJ, Fuertes A, Sanchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: An alert. AIDS 1999; 13(8):1004–1005.
   PubMed Web of Science ®Google Scholar
• Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother 2000; 34(3):405–407.
   Google Scholar
• Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41(14):1153–1193.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap CB. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80(6):668–681.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78(6):593–604.
   PubMed Web of Science ®Google Scholar
• Eap CB, Bourquin M, Martin J, Spagnoli J, Livoti S, Powell K, Baumann P, Deglon J. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000; 61(1):47–54.
   PubMed Web of Science ®Google Scholar
• Adinoff B. Divided doses for methadone maintenance. Am J Psychiatry 2008; 165(3):303–305.
   Google Scholar
• Barlett JG, Lane HC and al panel on antiretroviral guidelines for adults and adolescents. In Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Vol. 3. Washington, DC: Department of Health and Human Services, 2008; 1–139.
   Google Scholar
• Calvo R, Lukas JC, Rodriguez M, Carlos MA, Suarez E. Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz. Br J Clin Pharmacol 2002; 53(2):212–214.
   Google Scholar
• Kapadia F, Vlahov D, Wu Y, Cohen MH, Greenblatt RM, Howard AA, Cook JA, Goparaju L, Golub E, Richardson J, Wilson TE. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse 2008; 34(2):161–170.
   PubMed Web of Science ®Google Scholar
• Santos CQ, Adeyemi O, Tenorio AR. Attitudes toward directly administered antiretroviral therapy (DAART) among HIV-positive inpatients in an inner city public hospital. AIDS Care 2006; 18(7):808–811.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: The importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis 2005; 41(Suppl. 1):S89–S95.
   Google Scholar
• McCance-Katz EF, Moody DE, Morse GD, Ma Q, Rainey PM. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict 2010: 19(1):30–37.
   Google Scholar
• Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: A cross-sectional study. Addiction 2007; 102(2):289–300.
   Google Scholar